JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
Read original at benzingaStocks · News reference
Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 12:10 PM
- Checked
- Aug 10, 2026, 12:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing
Read original at benzinga8-K filing — Replimune Group, Inc. (REPL)
Filed: 2026-08-14 AccNo: 0001104659-26-096483 Size: 266 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarReplimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from
Read original at benzinga